TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
BRIDGEWATER, N.J., April 27, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at the Deutsche Bank 42nd Annual Health Care Conference in Boston, MA on Thursday, May 4, 2017 at 10:40 a.m. ET.
Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE® (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare disorders, including pulmonary arterial hypertension (PAH). For more information, visit www.insmed.com.
Investor Contact: Laura Perry or Heather Savelle Argot Partners 212-600-1902 [email protected] [email protected]
